Corporate Banner
Satellite Banner
Crystallography
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Combines Its Life Sciences and Diagnostics Businesses

Published: Thursday, September 19, 2013
Last Updated: Thursday, September 19, 2013
Bookmark and Share
Decision follows Agilent's announcement that it plans to separate the company into two independent publicly traded companies.

Agilent Technologies Inc. announces it has combined its Life Sciences Group with its Diagnostics and Genomics business, naming Lars Holmkvist the new group's president and senior vice president of Agilent, effective immediately. Holmkvist was previously president of the Diagnostics and Genomics Group and senior vice president of Agilent.

The split will see one company focused on life sciences, diagnostics and applied markets, retaining the Agilent name, and the other focused on electronic measurement, which will be named later.

Agilent, the life sciences, diagnostics and applied markets company, will be comprised of two businesses - the Chemical Analysis Group, led by Mike McMullen, current group president and Agilent senior vice president, and the new Life Sciences and Diagnostics Group, under Holmkvist as its president. Nick Roelofs, who has been president of the Life Sciences Group, will leave Agilent to pursue other business opportunities.

"We are creating a new Agilent with a simplified structure that can move quickly to develop and deliver industry-leading total workflow solutions for our customers," said William (Bill) Sullivan, Agilent president and CEO. "Lars is the ideal leader for the new group with his years of experience, depth of market knowledge and superb leadership style."

Agilent also announced that with the spinoff of its electronic measurement business, it has created a new Agilent Order Fulfillment organization. Henrik Ancher-Jensen has been named president of Agilent Order Fulfillment and senior vice president of Agilent. He replaces Gooi Soon Chai, who is joining the electronic measurement spinoff company. Ancher-Jensen was previously vice president, Global Product Supply, for Agilent's Diagnostics and Genomics Group, and corporate vice president, Global Operations, for Dako.

"Henrik understands the priority of customer satisfaction while at the same time contributing to margin expansion goals. His experience and drive for excellence makes him a great match for this important position," Sullivan said.

"The new simplified organization positions an already strong set of businesses for greater growth and shareholder return," Sullivan said.

Lars Holmkvist
Holmkvist joined Agilent in June 2012, when Agilent acquired Dako. He had been president and CEO of Dako since 2009. Before joining Dako, Holmkvist served as president, Europe, for Applied Biosystems, where he was later promoted to president, International, with responsibilities for all commercial operations outside the U.S.

Holmkvist brings more than 25 years' experience within the medical device and pharmaceutical industries, where he has held increasingly significant roles in marketing, sales and business management. He holds a degree in economics from Handelshogskolan Sundsvall in Sweden.

Henrik Ancher-Jensen
Ancher-Jensen came to Agilent in June 2012 with the acquisition of Dako. He joined Dako in 2006 as vice president, Supply Chain, and chief information officer, and was subsequently promoted to corporate vice president, Global Operations. Prior to joining Dako, he spent more than 15 years in senior management roles and management consulting with Chr. Hansen, Deloitte Consulting and NVE. Ancher-Jensen holds a degree in economics from Aarhus University in Denmark.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Technologies Opens New X-ray Diffraction Manufacturing Facility
The state-of-the-art facility in Wroclaw, Poland gives Agilent significantly greater manufacturing capacity and enhanced R&D capabilities compared with the company's old facility.
Wednesday, November 21, 2012
Agilent Technologies Reports Fourth-Quarter 2012 Results
Revenues for the fourth fiscal quarter ended October 31, 2012 were $1.77 billion, up 2 percent one year ago.
Tuesday, November 20, 2012
Scientific News
Neutron Analysis of HIV-1 Protease
Neutrons probe structure of enzyme critical to development of next-generation HIV drugs.
Do Germs Cause Type 1 Diabetes?
Germs could play a role in the development of type 1 diabetes by triggering the body’s immune system to destroy the cells that produce insulin, new research suggests.
Crucial Reaction for Vision Revealed
Scientists have tracked the reaction of a protein responding to light, paving the way for a new understanding of life's essential reactions.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Serotonin Transporter Structure Revealed
Researchers determined the 3-D structure of the serotonin transporter and visualized how two common antidepressants interact with the protein.
Zika Virus Structure Revealed
Team at Purdue becomes the first to determine the structure of the Zika virus, which reveals insights critical to the development of effective antiviral treatments and vaccines.
Half a Million-Dollar Tick
How proteins present in tick saliva prevent the immune system from running amok.
Promising Model for Hantavirus Drug Design
X-ray crystallography provides drug template against disease transmitted by small rodents.
A Crystal Clear View of Biomolecules
Fundamental discovery triggers paradigm shift in crystallography.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!